Asset profile
Xanomeline/trospium chloride · Cobenfy
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Schizophrenia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also in development:Alzheimer's Disease · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
119 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 119 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Xanomeline / Trospium Chloride (Cobenfy): this drug | Approved | Small molecule | Muscarinic M1/M4 receptor (agonist/antagonist combination) | ||
| Aripiprazole (Abilify Maintena) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist) | ||
| Aripiprazole (Abilify MyCite) | Approved | Combination | Dopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist) | ||
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada Initio) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Aripiprazole Lauroxil (Aristada) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Asenapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Benzgalantamine (Zunveyl) | Approved | Small molecule | Acetylcholinesterase/nicotinic receptor (prodrug) | ||
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | ||
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | ||
| Clozapine | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | ||
| Dexmedetomidine (Igalmi) | Approved | — | — | ||
| Dexmedetomidine (Igalmi) | Approved | Small molecule | Alpha-2 adrenergic receptor (agonist) | ||
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA | ||
| Donanemab (Kisunla) | Approved | Monoclonal antibody | Amyloid-beta (monoclonal antibody) | ||
| Fazaclo | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) |
…and 104 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(31 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
October 2026 (2)
November 2026 (4)
Phase 3Bipolar-I Disorder With Mania or Mania With Mixed FeaturesRecruiting
Est. primary completion 2026-11-01 · NCT06951698 · CT.gov ↗
What to watch
Phase 3Bipolar Disorder Type I With Mania or Mania With Mixed FeaturesRecruiting
Est. primary completion 2026-11-02 · NCT06951711 · CT.gov ↗
What to watch
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2026-11-24 · NCT06585787 · CT.gov ↗
What to watch
Phase 4Healthy VolunteersRecruiting
Est. primary completion 2026-11-30 · NCT07681076 · CT.gov ↗
What to watch
2027 (6)
March 2027 (1)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2027-03-29 · NCT07063342 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1/2SchizophreniaRecruiting
Est. primary completion 2027-04-30 · NCT07423546 · CT.gov ↗
What to watch
June 2027 (2)
September 2027 (1)
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2027-09-07 · NCT05980949 · CT.gov ↗
What to watch
December 2027 (1)
Phase 4SchizophreniaRecruiting
Est. primary completion 2027-12-30 · NCT07221877 · CT.gov ↗
What to watch
2028 (7)
February 2028 (1)
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2028-02-21 · NCT06947941 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Bipolar Disorder Type I With ManiaRecruiting
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch
September 2028 (3)
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2028-09-11 · NCT06976216 · CT.gov ↗
What to watch
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2028-09-11 · NCT06976203 · CT.gov ↗
What to watch
Phase 3SchizophreniaRecruiting
Est. primary completion 2028-09-23 · NCT06882785 · CT.gov ↗
What to watch
2029 (6)
January 2029 (1)
Phase 3SchizophreniaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07084831 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2029-03-03 · NCT07686263 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Alzheimer's DiseaseRecruiting
Est. primary completion 2029-06-22 · NCT06937229 · CT.gov ↗
What to watch
August 2029 (2)
Phase 3Irritability Associated With Autism Spectrum DisorderNot yet recruiting
Est. primary completion 2029-08-06 · NCT07284745 · CT.gov ↗
What to watch
Phase 3Irritability Associated With Autism Spectrum DisorderNot yet recruiting
Est. primary completion 2029-08-06 · NCT07285798 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2029-12-18 · NCT07288567 · CT.gov ↗
What to watch
2030 (2)
March 2030 (1)
Phase 3SchizophreniaRecruiting
Est. primary completion 2030-03-08 · NCT07424404 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control …Not yet recruiting
Est. primary completion 2030-09 · NCT07721272 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorder, Memory LossNot yet recruiting
Est. primary completion 2031-12 · NCT07228338 · CT.gov ↗
What to watch
2032 (1)
June 2032 (1)
Phase 1/2Cocaine Use Disorder (CUD)Recruiting
Est. primary completion 2032-06-30 · NCT07624227 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.